2338 GMT - Macquarie serves up two contrarian ideas for investors as Australia's corporate-earnings season extends into its second week. It believes the market likely fears a CSL miss, given the pharmaceutical company's stock hasn't yet arrested a share-price slide that began in July and some analysts have cut forecasts. CSL's stock is down some 13% since July 23. "It should benefit from the lower AUD and pharma tends to outperform after RBA cuts," Macquarie says. Many economists expect Australia's central bank to cut interest rates this month, which would be the first time since inflation ran hot in the pandemic's aftermath. Macquarie is also bullish about property company Mirvac, saying it would also benefit from rate cuts. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 09, 2025 18:38 ET (23:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。